2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.053 Winston Gouldin NACLC23 Abstract

PP01.053 Winston Gouldin NACLC23 Abstract

Pdf Summary

The PERLA Trial is a phase 2 study evaluating the efficacy and safety of chemotherapy combined with PD-1 inhibitors (dostarlimab or pembrolizumab) as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) from the trial have been analyzed.<br /><br />Patients were randomized to receive either dostarlimab or pembrolizumab in combination with chemotherapy. PROs were collected at specified time points and analyzed using a longitudinal mixed model. A change of 10 points was considered clinically meaningful, and scores were categorized as improved, stable, or worsened. Time to deterioration (TTD) was also estimated.<br /><br />The analysis included a total of 102 patients in the dostarlimab arm and 99 patients in the pembrolizumab arm. The completion rates for PRO assessments at one year on treatment were 55% for the dostarlimab arm and 37.1% for the pembrolizumab arm. At the end of treatment, the completion rates were 100%.<br /><br />The results showed that PRO scores remained stable throughout the treatment period, with no significant differences observed between the two treatment arms. Most patients in both arms had stable or improved responses at one year on treatment. At this time point, patients receiving dostarlimab reported more frequent improvements in chest pain and dyspnea compared to those receiving pembrolizumab.<br /><br />The TTD on most PRO subscales was comparable between the two treatment arms. However, patients receiving dostarlimab had a longer TTD in dyspnea compared to those receiving pembrolizumab.<br /><br />Overall, these PRO results are consistent with the efficacy and safety data of the PERLA Trial and support further investigation of dostarlimab as a novel therapy for metastatic non-squamous NSCLC.

Keywords

PERLA Trial

chemotherapy

PD-1 inhibitors

metastatic non-squamous NSCLC

patient-reported outcomes

PROs

completion rates

chest pain

dyspnea

efficacy data